Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.55
- Piotroski Score 3.00
- Grade Neutral
- Symbol (RCEL)
- Company AVITA Medical, Inc.
- Price $12.57
- Changes Percentage (3.02%)
- Change $0.37
- Day Low $11.91
- Day High $12.73
- Year High $18.93
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $9.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.76
- Trailing P/E Ratio -5.2
- Forward P/E Ratio -5.2
- P/E Growth -5.2
- Net Income $-39,168,218
Income Statement
Quarterly
Annual
Latest News of RCEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
FC Barcelona Legend Hails Successor: 'He's Spectacular'
FC Barcelona's Sergio Busquets praised young talent Marc Casado on Spanish radio. Casado, from La Masia academy, impressed under coach Flick's system. Busquets noted Casado's superlative level, surpri...
By Forbes | 11 hours ago -
Barcelona tramway deploys Alstom APS catenary-free tech
Barcelona introduces Alstom's catenary-free technology on its tramway, enhancing sustainability and urban development. The new extension aims to carry 24,000 more passengers daily, aligning with the c...
By Yahoo! Finance | 1 day ago -
FC Barcelona Cconfirms Lamine Yamal Injury Recovery Timeframe
FC Barcelona announced that Lamine Yamal will be out for 2-3 weeks with a high right ankle sprain, and Robert Lewandowski will miss around 10 days due to a lower back injury....
By Forbes | 1 day ago
